Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sutro Biopharma (STRO) Shares Outstanding (Weighted Average) (2016 - 2025)

Sutro Biopharma's Shares Outstanding (Weighted Average) history spans 10 years, with the latest figure at $84.2 million for Q3 2025.

  • For Q3 2025, Shares Outstanding (Weighted Average) rose 12.35% year-over-year to $84.2 million; the TTM value through Sep 2025 reached $84.2 million, up 12.35%, while the annual FY2024 figure was $76.8 million, 27.7% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q3 2025 was $84.2 million at Sutro Biopharma, roughly flat from $84.6 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $84.6 million in Q2 2025 and bottomed at $45.9 million in Q1 2021.
  • The 5-year median for Shares Outstanding (Weighted Average) is $60.2 million (2023), against an average of $61.2 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) skyrocketed 97.89% in 2021 before it rose 1.29% in 2022.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $46.1 million in 2021, then rose by 10.02% to $50.7 million in 2022, then grew by 18.57% to $60.2 million in 2023, then grew by 27.7% to $76.8 million in 2024, then increased by 9.58% to $84.2 million in 2025.
  • Per Business Quant, the three most recent readings for STRO's Shares Outstanding (Weighted Average) are $84.2 million (Q3 2025), $84.6 million (Q2 2025), and $83.1 million (Q1 2025).